More than a third of people with Parkinson’s disease who are prescribed antipsychotics stop treatment within six months of starting, a new database analysis suggests. The data also indicate that rates of treatment discontinuation are lower with Nuplazid (pimavanserin) than with other antipsychotics. The findings were published in …
News
People with Parkinson’s disease experienced significantly more pain during periods without levodopa therapy, a small study concluded. This finding suggests that the presence, or worsening, of pain could might alert doctors to the need to adjust or review current medication use in this patient population. The study, “…
Ineffective stimulation was the primary complaint among people with Parkinson’s disease who use a pacemaker-like device for deep brain stimulation (DBS), according to a 10-year analysis of a federal database that tracks reports of adverse events involving medical devices in the U.S. Battery-related problems, impedance issues, and infections…
A £1.375 ($1.9) million grant from the Edmond J. Safra Foundation will support a pioneering clinical trial aimed at speeding the development of new therapies for Parkinson’s disease. “This project will revolutionise the way we perform clinical trials of potentially disease-modifying drugs for people with Parkinson’s,” Thomas Foltynie, PhD, MD, a…
A protein secreted by stem cells, known as pentraxin 3 (PTX3), promoted the repair of nerve cells damaged as a consequence of Parkinson’s disease in a mouse model, a study reported. These findings support further work into PTX3 as a potential therapy to slow or halt disease progression, its researchers noted.
Middle-aged and older autistic adults with no intellectual disabilities reported more prevalent Parkinson’s disease-like features — referred to as parkinsonism — compared with the general population, a study found. These findings provide important knowledge about aging disorders such as Parkinson’s among older people with autism spectrum disorder…
People who are gay, bisexual, or transgender with Parkinson’s disease or other movement disorders can be reluctant to disclose their sexual or gender identities for fear of being denied treatment or enrollment in clinical trials, a study found. Research is limited into this growing patient group, and best practice guidelines…
The formation of toxic clumps of the protein alpha-synuclein, a hallmark of Parkinson’s disease, was not affected by reducing levels of tau, a protein that also forms aggregates in both Parkinson’s and Alzheimer’s disease, a mouse study suggested. These results imply that the role of tau in…
The U.S. Food and Drug Administration (FDA) has approved a Phase 3 trial to test multiple infusions of fat-derived mesenchymal stem cells — ones obtained from healthy donors — in people with Parkinson’s disease. The Hope Biosciences Stem Cell Research Foundation (HBSCRF), which received the authorization, already has a…
Smoking history may not influence the severity of symptoms in Parkinson’s disease, a small study suggests. Moreover, in some individuals, exposure to cigarette smoke may worsen motor symptoms, which could lead patients to quit smoking and explain why smoking is more common among people without the disease. The study,…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s